The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway
Emre Delen, Oğuzhan Doğanlar
J Korean Neurosurg Soc. 2020;63(4):444-454.   Published online 2020 Jun 4     DOI: https://doi.org/10.3340/jkns.2019.0252
Citations to this article as recorded by Crossref logo
IFN-γ inhibits ovarian cancer progression via SOCS1/JAK/STAT signaling pathway
A. H. Gao, Y. R. Hu, W. P. Zhu
Clinical and Translational Oncology.2022; 24(1): 57.     CrossRef
Ruxolitinib attenuates secondary injury after traumatic spinal cord injury
Zhan-Yang Qian, Ren-Yi Kong, Sheng Zhang, Bin-Yu Wang, Jie Chang, Jiang Cao, Chao-Qin Wu, Zi-Yan Huang, Ao Duan, Hai-Jun Li, Lei Yang, Xiao-Jian Cao
Neural Regeneration Research.2022; 17(9): 2029.     CrossRef
Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma
Ying Bi, Zeng-Hong Wu, Fei Cao
BMC Cancer.2022;[Epub]     CrossRef
NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells
Neftali Vazquez, Alma Lopez, Victoria Cuello, Michael Persans, Erin Schuenzel, Wendy Innis-Whitehouse, Megan Keniry
Cancer Treatment and Research Communications.2021; 27: 100340.     CrossRef